Cumberland Pharma reports Q4 revenue up 31% to $13.7M; full-year adjusted earnings $1.7M

CUMBERLAND PHARMACEUTICALS INC

Full-year 2025 net revenue $44.5M (+18% YoY); net loss improved to $2.9M from $6.5M.
Adjusted earnings for 2025 were $1.7M vs. -$1.0M in 2024; operating cash flow $4.9M.
Debt reduced by $10M; credit facility balance $5.2M at year-end; shareholders equity $24.9M.
Vibativ approved in China; launched in Saudi Arabia; Talicia co-commercialization began Oct 2025.
Caldolor received permanent J-code (J1741) for CMS reimbursement in Dec 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.